https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44599 Mon 17 Oct 2022 16:08:38 AEDT ]]> Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54596 Mon 04 Mar 2024 08:42:35 AEDT ]]>